You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 674 A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patients

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
674 A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patients

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023422013
Dec 20239203
Jan 20247107
Feb 20244201
Mar 20247601
Apr 20244301
May 20245203
Jun 20244400
Jul 20244000
Aug 20242404
Sep 20243401
Oct 20246203
Nov 202411202
Dec 202410005
Jan 20254409
Feb 20252803
Mar 2025002
Apr 2025005
May 2025002
Jun 2025003
Total1286068